SAN DIEGO, Feb. 4, 2013 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc. ("Innovus Pharma"), www.innovuspharma.com , (OTCBB:INNV) today announced that Dr. Bassam Damaj, Ph.D., Chief Executive Officer, will present at the 15th Annual BIO CEO & Investor Conference, to be held at the Waldorf-Astoria Hotel in New York February 11-12, 2013. Dr. Damaj is scheduled to present on Monday, February 11th at 9:00 a.m. EST.
About Innovus Pharma
Innovus Pharma, headquartered in San Diego, CA, is an emerging pharmaceutical company that delivers innovative and uniquely presented and packaged healthcare solutions through both prescription medicines and consumer and health products.Innovus Pharma develops, in-licenses, acquires and markets proprietary respiratory, dermatology and autoimmune pharmaceutical products intended for better patient compliance and results. The Company is building a robust pipeline with a wide range of approved products, including arthritis pain relief product, APEAZ™, as well as product candidates across each phase of development, such as its VAP-1 program for psoriasis and dermatitis. APEAZ™ is an FDA-compliant, fast-acting and powerful arthritis pain relief cream, formulated to target the joints where arthritis resides. APEAZ™ is one of the most intensive over-the-counter ("OTC") topical treatments for pain relief available today. APEAZ™ is available in regular and extra-strength formulations. The product is designed to relieve: acute pain, arthritis pain, athletic injuries, muscle soreness and/or stiffness, muscle and joint pain, simple backache, strains and sprains. For further information about Innovus Pharma, go to http://www.innovuspharma.com Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may be considered to be "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that may individually or mutually impact the matters described in this release for a variety of reasons, many of which are outside the control of Innovus Pharma. These risks and uncertainties include, but are not limited to Innovus Pharma's ability to raise sufficient capital to fund its operations and growth strategy, the continued willingness of members of the Board of Directors to fund the company on an interim basis, Innovus Pharma's ability to achieve its development, regulatory, commercialization and financial goals for its existing products, its ability to acquire additional products, and its ability to achieve development, regulatory, commercialization and financial goals for such additional products. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or the "Investors" section of Innovus Pharma's website at innovuspharma.com.
CONTACT: Kevin Holmes Chesapeake Group firstname.lastname@example.org T: 410-825-3930